San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers, announced today the successful completion of its Series D funding round, raising $50 million. The financing was led by prominent healthcare investment firms Vida Ventures LLC and Longitude Capital, along with participation from Sofinnova Investments, Surveyor Capital, Avidity Partners, and AbbVie.

Quanta Therapeutics, founded by renowned scientist Dr. Perry Nisen, is pioneering the development of best-in-class allosteric inhibitors to target previously undruggable RAS mutations in challenging-to-treat cancers, including lung, colon, and pancreatic cancer. While existing KRAS inhibitors have made significant strides in targeting the KRAS G12C mutation, these therapies are limited to approximately ten percent of KRAS-driven cancers and are currently approved only for non-small cell lung cancer patients in later lines of therapy.

The company's primary focus is on modulating RAS signaling at the cell membrane, aiming to expand the scope of treatable RAS-driven cancers. Leveraging deep biologic insights, novel protein conformation detection technology, and sophisticated medicinal chemistry expertise, Quanta Therapeutics is dedicated to developing next-generation oral small molecules that have the potential to revolutionize KRAS therapy.

"We are thrilled to have secured this substantial funding in our Series D round, which will propel our efforts in combating RAS-driven cancers," said Dr. Perry Nisen, Founder of Quanta Therapeutics. "This financing enables us to advance our groundbreaking research and expedite the development of novel allosteric inhibitors that can address the unmet needs of patients suffering from a range of RAS-driven cancers."